ERRATUM

Erratum to: Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease

Saima Hassan, MD, PhD, FRCSC^{1,2}, Teresa M. Petrella, MD, MSc, FRCPC³, Tong Zhang, MSc⁴, Suzanne Kamel-Reid, BA, MA, PhD, FACMG⁴, Francesco Nordio, PhD⁵, Andrea Baccarelli, MD, PhD⁶, Shachar Sade, MD, MSc, FRCPC⁷, Karen Naert, MD, FRCPC⁴, Ayman Al Habeeb, MBBS, FRCPC⁴, Danny Ghazarian, MB ChB, PhD, FRCPC, FCAP⁴, and Frances C. Wright, MD, MEd, FRCSC¹

¹Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, ON, Canada;

²Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR; ³Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; ⁴Department of Pathology, University Health Network, Toronto, ON, Canada; ⁵Department of Medicine, Brigham and Women's Hospital, Boston, MA; ⁶Department of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA; ⁷Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

ERRATUM TO: ANN SURG ONCOL DOI 10.1245/S10434-014-4199-Z

In the original article, the first sentence in the Results section of the abstract is incorrect. The corrected sentence is as follows:

Ten patients (10/31, 32.3 %) achieved a pathologic complete response (pCR), 17/31 (54.8 %) had a partial response, and 4/31 (12.9 %) had progressive disease on treatment.

The online version of the original article can be found under doi:[10.1245/s10434-014-4199-z](https://doi.org/10.1245/s10434-014-4199-z).

© Society of Surgical Oncology 2014

Published Online: 12 December 2014

F. C. Wright, MD, MEd, FRCSC
e-mail: frances.wright@sunnybrook.ca